ProCE Banner Activity

Immunogenicity of Adjuvanted Herpes Zoster Subunit Vaccine in Patients With RA Treated With JAK Inhibitors vs Controls

Slideset Download
Conference Coverage
Preliminary results of this nonrandomized study suggest that 2 doses of the HZ/su vaccine produce satisfactory antibody responses and acceptable tolerability in a majority of patients with RA receiving JAK inhibitors.

Released: November 09, 2020

Expiration: November 08, 2021

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

Gilead Sciences, Inc.

Sanofi Genzyme Corp